Serum growth hormone in patients with carcinoid tumours; basal levels and response to glucose and thyrotrophin releasing hormone

1985 ◽  
Vol 109 (1) ◽  
pp. 13-18 ◽  
Author(s):  
Kjell Öberg ◽  
Ingrid Norheim ◽  
Leif Wide
Keyword(s):  
Growth Hormone ◽  
Glucose Load ◽  
Serum Growth Hormone ◽  
Thyrotrophin Releasing Hormone ◽  
Growth Hormone Releasing Factor ◽  
Releasing Hormone ◽  
Carcinoid Tumours ◽  
Control Subjects ◽  
Specific Stimulation ◽  
Serum Gh

Abstract. The regulation of serum growth hormone was studied in 33 consecutive patients with carcinoid tumours; both diurnal serum GH and GH responses to an i.v. glucose load and TRH were assessed. Seventeen of the patients (52%) showed disturbed regulation of serum GH and 10 had at least two abnormal tests. Four patients had clinically overt acromegaly. The diurnal mean serum GH levels were higher (P < 0.001) in patients with carcinoid tumours than in control subjects and more than one third (41%) had levels in a range similar to that of acromegalic patients without carcinoid tumours. The disturbance in serum GH regulation might have been caused in some patient by tumour secreted growth hormone releasing factor(s) which act directly on pituitary somatotrophs, but other tumour-related non-specific stimulation must be considered. Carcinoid tumours should be considered in the aetiology of acromegaly.

Hypothalamic hormones that release growth hormone stimulate hepatic 5′-monodeiodination activity in the chick embryo

1988 ◽  
Vol 118 (2) ◽  
pp. 233-236 ◽  
Author(s):  
E. R. Kühn ◽  
A. Vanderpooten ◽  
L. M. Huybrechts ◽  
E. Decuypere ◽  
V. Darras ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Plasma Concentration ◽  
Chick Embryo ◽  
Chick Embryos ◽  
Thyrotrophin Releasing Hormone ◽  
Growth Hormone Releasing Factor ◽  
Releasing Hormone ◽  
Pancreatic Growth ◽  
Hypothalamic Hormones ◽  
Plasma Gh

ABSTRACT Plasma GH, tri-iodothyronine (T3), thyroxine (T4) and liver 5′-monodeiodination (5′-D) activity were measured in 18-day-old chick embryos injected with thyrotrophin-releasing hormone (TRH) and human pancreatic growth hormone releasing factor (hpGRF). Injections of 0·1 and 1 μg TRH and 1·5 μg hpGRF increased the concentration of plasma GH while injection of 15 μg hpGRF had no effect. Concentrations of plasma T3 were raised after injection of TRH or hpGRF. Injections of TRH but not of hpGRF raised the concentration of plasma T4. The increases in concentration of plasma T3 after injection of TRH or hpGRF were parallelled by increases in liver 5′-D activity. An injection of 0·25 μg T4 significantly raised the concentration of T4 in plasma but had no effect on plasma T3 or liver 5′-D activity. It is concluded that the release of chicken GH by TRH or hpGRF is responsible for the observed increases in plasma concentration of T3 and liver 5′-D activity. J. Endocr. (1988) 118, 233–236

Inhibition of dopamine-induced release of growth hormone by thyrotropin-releasing hormone.

1977 ◽  
Vol 233 (5) ◽  
pp. E430
Author(s):  
R A Steiner ◽  
P Illner ◽  
P Marques ◽  
D Williams ◽  
L Shen ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Growth Hormone ◽  
Intravenous Infusion ◽  
Serum Insulin ◽  
Thyrotropin Releasing Hormone ◽  
Adolescent Male ◽  
Serum Growth Hormone ◽  
Releasing Hormone ◽  
Effective Doses ◽  
Serum Gh

The effects of thyrotropin-releasing hormone (TRH) and dopamine (DA) on serum growth hormone (GH) levels were examined in the adolescent male baboon. Intravenously administered DA (40 microgram/kg-min-1 for 20 min) raised serum GH and glucose and lowered serum insulin concentrations but caused no increase in blood pressure. Concomitant intravenous infusion of TRH at 2 doses (96 ng/kg-min-1 and 40 microgram/kg-min-1 for 20 min) blocked the DA-induced increase in serum GH. The relatively low effective doses of TRH used to suppress the DA-induced GH increase suggest an interaction with catecholamines at the hypothalamic and/or pituitary to influence GH release.

scholarly journals Response of growth hormone to various doses of growth hormone releasing factor and thyrotropin releasing hormone administered separately and in combination to dairy calves

1991 ◽  
Vol 71 (4) ◽  
pp. 1045-1052 ◽  
Author(s):  
Peter Løvendahl ◽  
John A. Woolliams ◽  
Patrick A. Sinnett-Smith
Keyword(s):  
Growth Hormone ◽  
Area Under The Curve ◽  
Multiplicative Model ◽  
Thyrotropin Releasing Hormone ◽  
Dairy Calves ◽  
Serum Growth Hormone ◽  
Growth Hormone Releasing Factor ◽  
Releasing Hormone ◽  
The Mean ◽  
Multiplicative Effects

Doses of growth hormone releasing factor (GRF) and thyrotropin releasing hormone (TRH) and combinations of these were administered by intravenous injection to six calves aged 155 ± 3 days and weighing 136 ± 16 kg. Injections were at 09:00, 12:00 and 15:00 h on 4 days, and doses were 0, 15, 30 and 60 pmol GRF kg−1 and 0, 275, 550 and 1100 pmol TRH kg−1, with GRF plus TRH at all combinations of these doses. Response of serum growth hormone (GH) was measured as the mean at 5, 10, 15 and 20 min following injection (PEAK) and the area under the curve during 0–60 min (AUC). The correlation between PEAK and AUC was 0.98. The variation in PEAK was related to GH prior to injection and to PEAK 3 h earlier. Separate multiplicative effects for each secretagogue were fitted, with the effects related to the logarithm of dose. Doubling the dose increased PEAK by 1.46-fold following GRF (P < 0.05) and 1.25-fold following TRH (P < 0.05). There was no evidence that the results for either secretagogue were affected by the presence or absence of the other. This multiplicative model provides a description of the synergy between these secretagogues. Key words: GH-release, GRF, TRH, calves, dose response

The effects of intranasal insufflation of growth hormone releasing factor analogie GRF1 – 29 NH2 on growth hormone secretion in children with short stature

1986 ◽  
Vol 113 (4_Suppl) ◽  
pp. S135-S138 ◽  
Author(s):  
M. BORKENSTEIN
Keyword(s):  
Growth Hormone ◽  
Short Stature ◽  
Gh Deficiency ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Normal Children ◽  
Serum Growth Hormone ◽  
Growth Hormone Releasing Factor ◽  
Serum Gh ◽  
Synthetic Growth

ABSTRACT The effects of intranasal insufflation of the synthetic growth hormone releasing factor GRF 1-29-NH2 on serum growth hormone (GH) were investigated in five healthy prepubertal children with short stature. 100 μg/kg/body weight of synthetic GRF 1-29-NH2, 500 μg in 100 μl water, were insufflated intranasally after careful cleaning of the nose. GRF 1-29-NH2 induced a prompt rise of serum GH levels with peak values at 15 minutes in all children investigated. Peak serum GH values were 28.3 ± 12.0 ng/ml (x̄ ± SD), range 17.1 - 47.6 ng/ml; Δ was 27.0 ± 12.2 ng/ml (x̄ ± SD). Serum GH levels were still significantly raised 120 minutes after the insufflation of GRF 1-29-NH2 (p < 0.05). No side effects, except for burning of the nasal mucosa in one patient, were observed. The results of this study demonstrate that intranasal insufflation of synthetic GRF 1-29-NH2 induces a prompt release of GH in otherwise normal children with short stature. Pulsatile intranasal insufflation of GRF 1-29-NH2 probably could be used for the treatment of some children with GH deficiency due to a defect at a suprapituitary level.

Sign in / Sign up

Export Citation Format

Share Document